{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Corticosteroid&page=7",
    "query": {
      "condition": "Corticosteroid",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 690,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Corticosteroid&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Corticosteroid&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T19:31:09.616Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03629249",
      "title": "Systemic Corticosteroids Avoidance Study in Severe Asthma Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo once daily",
          "type": "DRUG"
        },
        {
          "name": "QAW039 150 mg once daily",
          "type": "DRUG"
        },
        {
          "name": "QAW039 450 mg once daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 604,
      "start_date": "2018-12-13",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 9,
      "location_summary": "Newport Beach, California • Westminster, California • Winter Park, Florida + 6 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Bangor",
          "state": "Maine"
        },
        {
          "city": "Waldorf",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03629249"
    },
    {
      "nct_id": "NCT04157348",
      "title": "Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Granulomatous Vasculitis"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Benralizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 140,
      "start_date": "2019-10-29",
      "completion_date": "2026-11-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 9,
      "location_summary": "Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04157348"
    },
    {
      "nct_id": "NCT05885555",
      "title": "A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "Ianalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 41,
      "start_date": "2023-08-16",
      "completion_date": "2029-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05885555"
    },
    {
      "nct_id": "NCT01184014",
      "title": "Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "NPH insulin plus Complete Insulin Orders",
          "type": "DRUG"
        },
        {
          "name": "Complete Insulin Orders",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HealthPartners Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2010-08",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-13",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 1,
      "location_summary": "Saint Louis Park, Minnesota",
      "locations": [
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01184014"
    },
    {
      "nct_id": "NCT03793439",
      "title": "Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoidosis, Pulmonary",
        "Sarcoidosis Lung",
        "Sarcoidosis"
      ],
      "interventions": [
        {
          "name": "Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial",
          "type": "DRUG"
        },
        {
          "name": "Spirometry",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "RNA Sequencing",
          "type": "GENETIC"
        },
        {
          "name": "Laboratory testing",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib 5mg [Xeljanz] 1 year open-label extension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "GENETIC"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 5,
      "start_date": "2019-05-15",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-02-18",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03793439"
    },
    {
      "nct_id": "NCT00063752",
      "title": "Safety Study of PI-0824 to Treat Pemphigus Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pemphigus Vulgaris"
      ],
      "interventions": [
        {
          "name": "PI-0824",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peptimmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2003-07",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Salisbury, Massachusetts + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Salisbury",
          "state": "Massachusetts"
        },
        {
          "city": "East Setauket",
          "state": "New York"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00063752"
    },
    {
      "nct_id": "NCT07787117",
      "title": "QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "None (observational study)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 8681,
      "start_date": "2026-08-03",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07787117"
    },
    {
      "nct_id": "NCT05638932",
      "title": "Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aetion, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1442,
      "start_date": "2020-06-16",
      "completion_date": "2023-09-25",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05638932"
    },
    {
      "nct_id": "NCT00223262",
      "title": "Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Memory Impairment Due to Corticosteroid Use",
        "Hypomania Due to Corticosteroid Use",
        "Hippocampal Atrophy Due to Corticosteroid"
      ],
      "interventions": [
        {
          "name": "Lamotrigine (Drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 28,
      "start_date": "2002-08",
      "completion_date": "2005-09",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00223262"
    },
    {
      "nct_id": "NCT07804446",
      "title": "Patient Pain and Function in Medial Knee Osteoarthritis After Anteromedial vs Anterolateral Intra-Articular Corticosteroid Injection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthitis",
        "Osteoarthritic Knee Pain",
        "Osteoarthritis (OA)",
        "Osteoarthritis (OA) of the Knee",
        "Osteoarthritis in the Knee"
      ],
      "interventions": [
        {
          "name": "Anteromedial Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Anterolateral Injection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2026-08-31",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-03T19:31:09.616Z",
      "location_count": 5,
      "location_summary": "Bolingbrook, Illinois • Chicago, Illinois • La Grange, Illinois + 2 more",
      "locations": [
        {
          "city": "Bolingbrook",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "La Grange",
          "state": "Illinois"
        },
        {
          "city": "Orland Park",
          "state": "Illinois"
        },
        {
          "city": "Woodridge",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07804446"
    }
  ]
}